Pentara to present five Alzheimer’s studies at AAIC 2026

Pentara will present five original research studies at the Alzheimer’s Association International Conference in London from July 12-15, 2026. The work focuses on anti-amyloid treatment durability, biomarker thresholds, equitable trial enrollment and trial design as drug developers look for better ways to test potential therapies.

Why it matters: - Pentara’s research targets some of the most difficult problems in Alzheimer’s drug development, including how long anti-amyloid treatments work and how to make clinical trials more inclusive. - The studies could influence how sponsors design trials, choose biomarkers, and interpret results in early Alzheimer’s disease. - The conference exposure also puts Pentara in front of sponsors, researchers and industry partners at a key scientific gathering for the field.

What happened: - Pentara will present five original studies at the Alzheimer’s Association International Conference, or AAIC, in London from July 12-15, 2026. - Pentara will also meet with sponsors, researchers and industry partners at Booth #100 during the conference. - Suzanne Hendrix, Ph.D., Pentara’s CEO, will present two studies. - Samuel Dickson, Ph.D., Garrett Duncan, M.S., and Caleb Dayley, M.S., will each present one study.

The details: - Suzanne Hendrix’s first presentation is titled “Continued or Time-Limited Treatment Benefits of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease.” - Suzanne Hendrix’s second presentation is titled “Quantifying the Improved Treatment Effect of Lecanemab and Donanemab in Minority Populations with Comorbidities.” - Samuel Dickson’s study is titled “Racial-Specific Biomarker Cutoff Is Needed to Increase Inclusion in Alzheimer's Clinical Trials.” - Garrett Duncan’s study is titled “Quantifying the Synergistic Treatment Effect of Lecanemab and Donanemab in Comorbid Populations.” - Caleb Dayley’s study is titled “Optimizing Pre-Symptomatic Alzheimer's Trials: A Power Comparison of Continuous Endpoints vs. Time-to-Event Analysis.” - Pentara said the presentations address durability of anti-amyloid therapies, efficacy in the presence of comorbidities, representation in clinical trials, biomarker selection and study design. - AAIC is described as the world’s largest scientific conference focused on Alzheimer’s disease and related dementias. - Pentara partners with sponsors, CROs and research organizations on statistical consulting, biostatistics and data management. - More information is available at pentara.com.

Between the lines: - The study list points to a broader industry push to solve not just whether Alzheimer’s drugs work, but for whom they work best and how trial methods can measure that more accurately. - The emphasis on minority populations and racial-specific biomarker cutoffs reflects growing pressure to improve representation in clinical research. - The mix of treatment-duration, biomarker and endpoint analyses suggests Pentara is positioning itself as a methodology partner, not just a data-analysis shop.

What's next: - Pentara will present the studies during AAIC 2026 and use the conference to connect with potential sponsors and collaborators. - The findings may help shape future Alzheimer’s clinical development programs and trial design decisions. - Additional discussion and business development are likely to continue after the conference as sponsors evaluate the methods and results.

The bottom line: - Pentara is using AAIC 2026 to showcase five studies aimed at making Alzheimer’s trials more precise, more inclusive and more useful for drug development.